Keqian Biology(SH:688526)2021-10-27 16:00Financial Performance - The company's operating revenue for Q3 2021 was ¥230,684,262.16, a decrease of 7.42% compared to the same period last year[6]. - The net profit attributable to shareholders for Q3 2021 was ¥99,764,687.76, down 27.10% year-on-year[6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥97,914,722.20, a decrease of 26.21% compared to the previous year[10]. - Total operating revenue for the first three quarters of 2021 reached ¥775,730,840.29, an increase of 28.4% compared to ¥604,280,090.12 in the same period of 2020[40]. - Net profit for the first three quarters of 2021 was ¥385,906,499.83, representing a growth of 24.5% from ¥309,739,673.87 in the same period of 2020[43]. - The net profit attributable to the parent company's shareholders was approximately ¥385.91 million, an increase from ¥319.74 million in the previous year, representing a growth of about 20.7%[46]. - The total comprehensive income attributable to the parent company's owners was approximately ¥385.91 million, compared to ¥319.74 million in the same period last year, reflecting a year-over-year increase of approximately 20.7%[49]. Research and Development - The company's R&D investment totaled ¥18,534,290.75 for the quarter, representing 8.03% of operating revenue, an increase of 1.76 percentage points year-on-year[10]. - The company reported a significant increase in R&D investment by 39.16% year-to-date, reflecting a commitment to product development[18]. - The company has obtained 37 new veterinary drug registration certificates, with 29 achieved through collaboration with Huazhong Agricultural University[26]. - The total investment in the research and development of the inactivated vaccine for duck Tembusu virus (DF2 strain) reached CNY 2,841,584.56, resulting in the acquisition of a new veterinary drug certificate[27]. - The company is currently in the clinical trial phase for the pig infectious gastroenteritis, pig epidemic diarrhea, and pig delta coronavirus trivalent inactivated vaccine[29]. - The company has invested CNY 7,389,377.72 in the research of the pig pseudorabies gE deletion inactivated vaccine, which has successfully obtained a new veterinary drug certificate[29]. - The company has signed a cooperation research framework agreement with Huazhong Agricultural University, ensuring competitive negotiation for future R&D projects[26]. - The company has established a management system for cooperative R&D, ensuring compliance with disclosure requirements for projects with Huazhong Agricultural University[26]. - The company has invested CNY 1,521,716.97 in the approval of standards for the African swine fever virus real-time fluorescence PCR detection kit[27]. - The company is in the new veterinary drug registration review stage for the pig circovirus type 2 and Actinobacillus pleuropneumonia bivalent inactivated vaccine[27]. Assets and Liabilities - The total assets at the end of the reporting period were ¥3,642,376,911.53, an increase of 17.08% from the end of the previous year[10]. - The total equity attributable to shareholders at the end of the reporting period was ¥2,961,439,090.75, up 9.34% from the previous year[10]. - Cash and cash equivalents as of September 30, 2021, amounted to ¥2,023,044,110.34, an increase of 5.8% from ¥1,913,957,581.53 at the end of 2020[34]. - Inventory as of September 30, 2021, was ¥115,059,745.91, up 62.0% from ¥71,069,415.33 at the end of 2020[34]. - Total liabilities as of September 30, 2021, were ¥680,393,401.41, up 69.2% from ¥402,401,915.72 at the end of 2020[40]. - The company reported a significant increase in accounts receivable, which rose to ¥191,639,389.05, a 25.3% increase from ¥152,885,424.94 at the end of 2020[34]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥473,820,698.63, an increase of 32.01% year-on-year[10]. - Cash inflow from operating activities totaled approximately ¥871.71 million, up from ¥632.25 million, marking an increase of approximately 37.8%[48]. - The net cash flow from operating activities was approximately ¥473.82 million, compared to ¥358.92 million in the previous year, representing an increase of about 32%[52]. - Cash inflow from investment activities was approximately ¥909.20 million, significantly higher than ¥155.54 million in the previous year, indicating a substantial increase of about 484.5%[52]. - The net cash flow from investment activities was negative at approximately -¥314.67 million, an improvement from -¥745.80 million in the previous year[52]. - The net increase in cash and cash equivalents was approximately ¥43.16 million, a significant decrease from ¥828.46 million in the previous year[54]. - The ending balance of cash and cash equivalents was approximately ¥514.21 million, down from ¥884.50 million in the previous year[54]. - The company reported a cash outflow from financing activities of approximately ¥210.37 million, compared to an inflow of ¥1,218.26 million in the previous year, indicating a significant change in financing strategy[52]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 11,076[19]. - The company has a total of 3,844,400 shares available for trading without restrictions, following strategic placement by China Merchants Securities[25]. - The company has a total of 16,800,000 shares held by Muyuan Industrial Group, accounting for 3.61% of total shares[22]. - Basic and diluted earnings per share were both ¥0.83, a decrease from ¥0.87 in the previous year, indicating a decline of about 4.6%[49].